Immunex Message Board - Msg: 16219767

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mark Bong who wrote (551)	8/16/2001 12:54:08 PM
From: scaram(o)uche	Read Replies (2) of 656

[ off topic ] >> clarification << Clarification? Obfuscation is more like it. The P-Z report said "BioTransplant's cell separation technology could capture a substantial portion of the market". That's Eligix only. That's not Eligix plus AlloMune, conditioning, or whatever. Moreover, the B cell device is targeted to autologous transplant. The P-Z estimate of "substantial portion" is absurd. Period. Any effort to justify it is absurd. Period. >> there are over 60,000 procedures performed worldwide now, and this would make the average cost of each procedure between $60-$65K, which seems reasonable. << All true. All irrelevant.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next